In addition, the identification of somatic mutation in the gene encoding the serine–threonine protein kinase B-RAF(B-RAF) in the majority of melanoma cases has provided an opportunity to treat these patients successfully with B-RAF inhibitors (38). This evidence concerns the gene BRAF and melanoma.